The reduced levels of MCP-1 in the BA-treated mice partially explain the dramatic reduction in metastatic tumour burden observed at the endpoint since most metastatic nodules were identified in the omentum regardless of treatment. The gene discussed is CCL2; the disease is neoplasm.